Skip to main content
Caplight Logo









HEPHAISTOS-Pharma

HEPHAISTOS-Pharma

Private
OrsayHealthcare & Life Scienceshttps://hephaistos-pharma.fr/

Last Round

Seed

May 16, 2024

Total Funding Raised

$4.88M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

HEPHAISTOS-Pharma is a biotechnology company developing innovative oncology treatments through a platform that enhances immune responses and transforms cold tumors into targets for effective cancer therapies.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Government Contracts, Services & Consulting

AI Layer

Non-AI

Keywords

immunotherapyoncologysolid tumor treatmentinnate immune systemTLR4 agonistbiotech R&Ddrug discoverypreclinical developmentcancer immunotherapybiopharmaclinical trialsdrug candidateprecision medicinebiotech startup

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

HEPHAISTOS-Pharma Comparables

Compare HEPHAISTOS-Pharma with similar companies based on industry and business-model similarity.

HEPHAISTOS-Pharma comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Tallac Therapeutics
83%
Stimunity
81%
Ipsen
78%

HEPHAISTOS-Pharma Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedMay 16, 2024

Key People

Founding team and executive leadership

Frederic CAROFF

CEO

Executive Team

Christel Lonneux

CFO

Executive Team

HEPHAISTOS-Pharma Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 27, 2026

    Grew 19% QoQ, from 16 to 19 employees.

  • May 16, 2024

    $4.88M raised from Elaia Partners and Noshaq.

HEPHAISTOS-Pharma Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

HEPHAISTOS-Pharma Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about HEPHAISTOS-Pharma's valuation, stock price, and market status.

Firmographic Details

HeadquartersOrsay
Employee Range19
Year Founded2018
Last FundingMay 16, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?